Talk:Macular edema

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.
	This article is supported by the Ophthalmology task force.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Macular edema.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Edit request

{{Requested edit}} April is posting on behalf of Alimera, and I am proposing this update to the approved treament section. --AprilE1234 (talk) 15:48, 28 June 2012 (UTC)[reply]

Iluvien

Iluvien, a sustained release intravitreal implant developed by Alimera Sciences, has been approved in Austria, Portugal and the U.K. for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Additional EU country approvals are anticipated.^[1]

Done RudolfRed (talk) 03:01, 7 July 2012 (UTC)[reply]

References

^ "Iluvien gains marketing authorization in Portugal for chronic DME". OSN SuperSite, June 7, 2012. Retrieved June 20, 2012

[1] "Iluvien gains marketing authorization in Portugal for chronic DME". OSN SuperSite, June 7, 2012. Retrieved June 20, 2012

[1]

Talk:Macular edema

Edit request

Iluvien

Navigation menu

Search